Anita J Bechtholt1, Gregory P Mark. 1. Department of Behavioral Neuroscience, Oregon Health & Science University, School of Medicine, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098, USA.
Abstract
RATIONALE: Drugs with addictive liability have a high probability of co-abuse in many addicts. For example, cocaine users are several times more likely to smoke cigarettes than non-cocaine users, and smoking increases during cocaine use. Previous work has provided evidence that nicotine and cocaine have interactive neurochemical effects, particularly with regard to dopamine (DA) transmission. OBJECTIVES: The present study examined the impact of nicotine treatment on the reinforcement efficacy of self-administered cocaine and non-reinforced responding for cocaine in rats. METHODS: Rats were trained to self-administer cocaine (i.v.) on a progressive ratio (PR) schedule of reinforcement. Self-administration training continued until stable responding was obtained. Acute nicotine pretreatment consisted of a subcutaneous injection (0.15, 0.3 and 0.6 mg/kg) 3 min prior to cocaine access. In the repeated treatment condition, a separate group of animals was given nicotine (0.6 mg/kg, s.c.) 3 min prior to cocaine access for 14 consecutive days. During extinction trials, these animals were injected with nicotine (0.6 mg/kg, s.c.) after 45 min of non-reinforced responding. RESULTS: Acute nicotine treatment produced an inverted U-shaped dose-response function with lower doses increasing and the highest dose decreasing the number of cocaine infusions obtained during a session. Animals treated repeatedly with the highest dose of nicotine showed a significant increase in the number of cocaine infusions by day 8 of nicotine treatment. During extinction sessions when cocaine was not available, injections of nicotine in these animals caused a reinstatement of the previously rewarded lever-press behavior. CONCLUSIONS: These findings indicate that nicotine can facilitate cocaine reinforcement, may contribute to the transition from moderate drug-taking to an escalation of drug intake which is characteristic of addiction, and may trigger relapse.
RATIONALE: Drugs with addictive liability have a high probability of co-abuse in many addicts. For example, cocaine users are several times more likely to smoke cigarettes than non-cocaine users, and smoking increases during cocaine use. Previous work has provided evidence that nicotine and cocaine have interactive neurochemical effects, particularly with regard to dopamine (DA) transmission. OBJECTIVES: The present study examined the impact of nicotine treatment on the reinforcement efficacy of self-administered cocaine and non-reinforced responding for cocaine in rats. METHODS:Rats were trained to self-administer cocaine (i.v.) on a progressive ratio (PR) schedule of reinforcement. Self-administration training continued until stable responding was obtained. Acute nicotine pretreatment consisted of a subcutaneous injection (0.15, 0.3 and 0.6 mg/kg) 3 min prior to cocaine access. In the repeated treatment condition, a separate group of animals was given nicotine (0.6 mg/kg, s.c.) 3 min prior to cocaine access for 14 consecutive days. During extinction trials, these animals were injected with nicotine (0.6 mg/kg, s.c.) after 45 min of non-reinforced responding. RESULTS: Acute nicotine treatment produced an inverted U-shaped dose-response function with lower doses increasing and the highest dose decreasing the number of cocaine infusions obtained during a session. Animals treated repeatedly with the highest dose of nicotine showed a significant increase in the number of cocaine infusions by day 8 of nicotine treatment. During extinction sessions when cocaine was not available, injections of nicotine in these animals caused a reinstatement of the previously rewarded lever-press behavior. CONCLUSIONS: These findings indicate that nicotine can facilitate cocaine reinforcement, may contribute to the transition from moderate drug-taking to an escalation of drug intake which is characteristic of addiction, and may trigger relapse.
Authors: N D Volkow; J S Fowler; A P Wolf; R Hitzemann; S Dewey; B Bendriem; R Alpert; A Hoff Journal: Am J Psychiatry Date: 1991-05 Impact factor: 18.112
Authors: Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly Journal: Schizophr Res Date: 2012-05-14 Impact factor: 4.939
Authors: Xiu Liu; Anthony R Caggiula; Susan K Yee; Hiroko Nobuta; Alan F Sved; Robert N Pechnick; Russell E Poland Journal: Neuropsychopharmacology Date: 2006-06-21 Impact factor: 7.853
Authors: Gregory P Mark; Anthony E Kinney; Michele C Grubb; Xiaoman Zhu; Deborah A Finn; Sarah L Mader; S Paul Berger; Anita J Bechtholt Journal: Brain Res Date: 2006-10-13 Impact factor: 3.252
Authors: Emily M Jutkiewicz; Danielle M Nicolazzo; Myung N Kim; Margaret E Gnegy Journal: Psychopharmacology (Berl) Date: 2008-06-20 Impact factor: 4.530